{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:41:29Z","timestamp":1793320889844,"version":"4.5.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded\n                    <jats:italic>in vitro<\/jats:italic>\n                    , and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1105265","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:22:03Z","timestamp":1682472123000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["T cell immunotherapy for cervical cancer: challenges and opportunities"],"prefix":"10.3389","volume":"14","author":[{"given":"Lingfeng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Lanqing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Minglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lv","family":"Fa-hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060622","article-title":"Human papilloma virus-associated cervical cancer and health disparities","volume":"8","author":"Olusola","year":"2019","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2013.09.001","article-title":"HPV and HPV-associated diseases","volume":"27","author":"Dunne","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/jnci\/92.5.397","article-title":"Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. the atypical squamous cells of undetermined Significance\/Low-grade squamous intraepithelial lesions triage study (ALTS) group","volume":"92","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa074","article-title":"Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the united states","volume":"154","author":"Kaufman","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001134","article-title":"Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial","volume":"30","author":"Nunes de Arruda","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00027","article-title":"Augmented package of palliative care for women with cervical cancer: Responding to refractory suffering","volume":"7","author":"Krakauer","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2174\/0929867327666200128105459","article-title":"The roles of programmed cell death ligand-1\/Programmed cell death-1 (PD-L1\/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy","volume":"28","author":"Zhang","year":"2021","journal-title":"Curr Med Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: Current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"B10","article-title":"Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer","volume":"2","author":"Kono","year":"1996","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9481","article-title":"Th17 response in patients with cervical cancer","volume":"16","author":"Alves","year":"2018","journal-title":"Oncol Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v33i5.14353","article-title":"Effect of ex vivo-expanded \u03b3\u03b4-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice","volume":"33","author":"Li","year":"2010","journal-title":"Clin Invest Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.5527","article-title":"Tumor-infiltrating CD204+ M2 macrophages compared to T cells as a prognosticator for patients with uterine cervical adenocarcinoma","volume":"20","author":"Kawachi","year":"2016","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell therapy with TILs: Training and taming T cells to fight cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch"},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejcsup.2013.07.013","article-title":"Immunotherapy of melanoma","volume":"11","author":"Haanen","year":"2013","journal-title":"EJC Suppl."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.54","article-title":"Efficient nonviral sleeping beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity","volume":"16","author":"Peng","year":"2009","journal-title":"Gene Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: More than ease of access","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-1702(02)00190-9","article-title":"Human papillomavirus immortalization and transformation functions","volume":"89","author":"M\u00fcnger","year":"2002","journal-title":"Virus Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00285","article-title":"p53 family and cellular stress responses in cancer","volume":"4","author":"Pflaum","year":"2014","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001540","article-title":"The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation","volume":"102","author":"Scarth","year":"2021","journal-title":"J Gen Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2020","journal-title":"Front Microbiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: Facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.03.003","article-title":"The dynamic alternation of local and systemic tumor immune microenvironment during concurrent chemoradiotherapy of cervical cancer: A prospective clinical trial","volume":"110","author":"Li","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"A preliminary Rep N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000267","article-title":"Tumor-infiltrating lymphocyte therapy and neoantigens","volume":"23","author":"Robbins","year":"2017","journal-title":"Cancer J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discovery"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e122467","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer-current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.10.7046","article-title":"Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy","volume":"175","author":"Zhou","year":"2005","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7125","article-title":"Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy","volume":"173","author":"Robbins","year":"2004","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2011.02640.x","article-title":"Characterization and comparison of \u2018standard\u2019 and \u2018young\u2019 tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution","volume":"75","author":"Donia","year":"2012","journal-title":"Scand J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e60031","DOI":"10.1371\/journal.pone.0060031","article-title":"Co-Stimulation through 4-1BB\/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"8","author":"Chacon","year":"2013","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2261","article-title":"IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response","volume":"175","author":"Li","year":"2005","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-019-0743-4","article-title":"Immune checkpoint inhibitors in the treatment of virus-associated cancers","volume":"12","author":"Gao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S217264","article-title":"Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu","volume":"11","author":"Maskey","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12307-012-0097-8","article-title":"Location and density of immune cells in precursor lesions and cervical cancer","volume":"6","author":"Bedoya","year":"2013","journal-title":"Cancer Microenviron"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/BF01543104","article-title":"CD8+ T lymphocytes are recruited to neoplastic cervix","volume":"15","author":"Bell","year":"1995","journal-title":"J Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2018-0237","article-title":"Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3045","article-title":"Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy","volume":"35","author":"Sarnaik","year":"2017","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.40","article-title":"An HPV-E6\/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression","volume":"22","author":"Rice","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2019.07.017","article-title":"Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities","volume":"462","author":"Jiang","year":"2019","journal-title":"Cancer Lett"},{"key":"B63","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discovery"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2020.110403","article-title":"Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer","volume":"505","author":"Cho","year":"2020","journal-title":"J Theor Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for b-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better","volume":"34","author":"D\u2019Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jso.24627","article-title":"CAR T-cell therapy for pancreatic cancer","volume":"116","author":"DeSelm","year":"2017","journal-title":"J Surg Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3178","article-title":"Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism","volume":"47","author":"Hu","year":"2015","journal-title":"Nat Genet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091296","article-title":"Generation and functional characterization of PLAP CAR-T cells against cervical cancer cells","volume":"12","author":"Yekehfallah","year":"2022","journal-title":"Biomolecules"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S321402","article-title":"The antitumor activity of CAR-T-PD1 cells enhanced by HPV16mE7-pulsed and SOCS1-silenced DCs in cervical cancer models","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e19433","DOI":"10.1097\/MD.0000000000019433","article-title":"CTLA-4 rs5742909 polymorphism and cervical cancer risk: A meta-analysis","volume":"99","author":"Hu","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152782","article-title":"The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix","volume":"216","author":"Karpathiou","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0779-3","article-title":"Safety and tolerability of adoptive cell therapy in cancer","volume":"42","author":"Wolf","year":"2019","journal-title":"Drug Saf"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. a preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0142","article-title":"Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer","volume":"24","author":"Matsuda","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11864-020-00790-4","article-title":"The potential of immune checkpoint blockade in cervical cancer: Can combinatorial regimens maximize response? a review of the literature","volume":"21","author":"Chitsike","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.565857","article-title":"Potential application of chimeric antigen receptor (CAR)-T cell therapy in renal cell tumors","volume":"10","author":"Schepisi","year":"2020","journal-title":"Front Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040840","article-title":"Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy","volume":"13","author":"Schepisi","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:22:07Z","timestamp":1682472127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1105265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2023.1105265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1105265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"article-number":"1105265"}}